Elevar Therapeutics Appoints Dong-Gun Kim As New CEO To Lead Company’s Post-NDA Commercialization Strategy

Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Group and a fully integrated biopharmaceutical company focused on improving treatment options for patients with limited therapies, announced the appointment of Dong-Gun (DG) Kim as its new Chief Executive Officer. DG Kim will continue to serve simultaneously as CEO of HLB US and CEO of Immunomic Therapeutics, Inc., both of which operate within the HLB Group network.

DG Kim succeeds Dr. Bryan Kim, who will now concentrate fully on his role as CEO of Verismo Therapeutics, another HLB Group company. The leadership transition comes at a pivotal time for Elevar, as the company recently submitted New Drug Applications (NDAs) to the U.S. Food and Drug Administration for its two leading drug candidates. With these filings completed, Dr. Bryan Kim shifts his focus to guiding Verismo through several key milestones expected in the coming year.

On January 23, 2026, Elevar submitted an NDA for the combination of rivoceranib, its VEGFR-TKI drug candidate, with camrelizumab, an anti-PD-1 antibody developed by Hengrui Pharma. The combination is being proposed as a first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC), the most common form of liver cancer. A second NDA was submitted on January 27, 2026, for lirafugratinib, Elevar’s investigational therapy for cholangiocarcinoma (bile duct cancer) characterized by FGFR2 fusions or rearrangements. This application positions lirafugratinib as a potential second-line treatment for patients with this aggressive disease.

DG Kim stated that Dr. Bryan Kim has played a central role in advancing Elevar’s regulatory progress, helping the company reach the important stage of submitting NDAs for both key drug programs. He emphasized that the company is now preparing for the next steps: executing a strong commercialization strategy and working closely with the FDA throughout its review process.

Before stepping into his expanded leadership roles within HLB Group, DG Kim served as CEO of HLB Co. Ltd. His career spans more than three decades across mergers and acquisitions, corporate finance and investment management, with experience at major corporations, investment firms and legal institutions in both the United States and Korea. He holds an A.B. in Physics from Harvard College and a J.D. from Harvard Law School.